Clinical Trials Logo

Clinical Trial Summary

To demonstrate the efficacy of T1225 1.5% eye drops, in comparison to reference product, for the treatment of purulent bacterial conjunctivitis, and to assess the safety


Clinical Trial Description

The aim of the present study was to compare the efficacy and safety of T1225 1.5% eye drops administered BID for 3 days in comparison to reference antibiotic eye drops, tobramycin, for the treatment of purulent bacterial conjunctivitis. The study was conducted as a Phase III, multicentre, international, investigator-masked, randomised, parallel-group, non-inferiority study in newborns, children, and adults. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00357773
Study type Interventional
Source Laboratoires Thea
Contact
Status Completed
Phase Phase 3
Start date May 2004
Completion date June 2005

See also
  Status Clinical Trial Phase
Completed NCT00407589 - Systemic Pharmacokinetics of BOL-303224-A Phase 1
Terminated NCT03696342 - Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%. Phase 3
Withdrawn NCT03698045 - Safety and Tolerability of PRO-143 Ophthalmic Solution in Healthy Volunteers. Phase 1
Completed NCT03987178 - Microbiologic Alterations of the Conjunctiva of Hot Tub-soaking Ophthalmologists N/A
Completed NCT03519516 - Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects Phase 1
Withdrawn NCT01721694 - Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection Phase 3